Urologia Internationalis

Original Paper

The Correlation of p53 Protein Overexpression and p53 Antibodies in Serum of Patients with Transitional Cell Carcinoma of the Urinary Bladder

Wunderlich H.a · Hindermann W.b · Hüller M.c · Reichelt O.a · Werner W.a · Schubert J.a · Kosmehl H.b

Author affiliations

aDepartment of Urology, bInstitute of Pathology, and cInstitute of Clinical Chemistry, Friedrich Schiller University, Jena, Germany

Keywords: Transitional cell carcinomap53 proteinp53 autoantibodies

Related Articles for ""
Urol Int 2000;64:13–17
https://doi.org/10.1159/000030475

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: April 20, 2000
Issue release date: April 2000

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Abstract

Background: Mutations of p53 gene were demonstrated in many solid tumors with varying frequency. We analyzed the relationship between p53 protein expression in bladder cancer tissue, p53 autoantibodies in serum and the clinical course of 32 patients with and 10 patients without transitional cell carcinoma of the urinary bladder. Materials and Methods: In the 32 patients studied, bladder cancer was diagnosed as pTaG1–2 in 8 cases, pT1G2 in 6, pT1G3 in 7, pT2G2–3 in 7, pT3G2–3 in 3 and pT4 in 1 patient. Anti-p53 antibodies were detected by an enzyme-linked immunosorbent assay. Immunohistochemical staining was performed using a standardized alkaline phosphatase monoclonal anti-alkaline phosphatase method. To prove the statistical significance of tumor grading and staging, the Kruskal-Wallis test was applied (p < 0.01). The mean follow-up was 26 months. Results: We found 12.5% p53 autoantibody-positive sera without a statistically significant correlation with tumor grade (p = 0.0569) and category (p = 0.612). Three of 4 patients who had p53 autoantibody-positive sera died within 9 months. All of these sera-positive patients had p53 protein-positive tumor tissue. Control sera were all negative for p53 autoantibodies. Conclusion: This study shows a strong relationship between p53 protein overexpression and the occurrence of p53 autoantibody in bladder cancer. The expression of p53 autoantibodies seems to be an event in cases of bladder cancer with an unfavorable tumor-specific outcome. Because of the small number of cases and the short follow-up time, further quantitative studies will hopefully demonstrate whether this might be of prognostic importance.

© 2000 S. Karger AG, Basel



Related Articles:

References

  1. Torti FM, Lum BL: Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy. Cancer 1987;59:613.
    External Resources
  2. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang Z: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388–392.
    External Resources
  3. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK: Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:321–326.
    External Resources
  4. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49–53.
    External Resources
  5. Alfred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborn CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200–206.
    External Resources
  6. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Giroget J, Salmon RJ, Thomas G: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:4248.
  7. Lowe SW, Ruley HE, Jacks T, Houseman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;72:637–641.
  8. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer a review. Int J Cancer 1994;57:19.
  9. Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403–408.
    External Resources
  10. Cattoretti G, Pileri S, Parravicini C, Becker MHG, Poggi S, Bifluco C, Key G, D’Amato L, Sabattini E, Feudale E, Reynolds F, Gerdes J, Rilke F: Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 1993;171:83–98.
    External Resources
  11. Cordell JL, Falini B, Erber WN, Gosh AK, Abdulaizz Z, McDonald S, Pulford K, Stein H, Mason DY: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase. J Histochem Cytochem 1984;32:219–229.
    External Resources
  12. Gustmann C, Altmannsberger M, Osborn M, Griesser H, Feller AC: Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkins lymphomas. Am J Pathol 1991;138:1413–1425.
    External Resources
  13. Burkhard FC, Markwalder R, Thalmann GN, Studer UE: Immunohistochemical determination of p53 overexpression. An easy and readily available method to identify progression in superficial bladder cancer? Urol Res 1997;25:31–35.
    External Resources
  14. Lane DP: A death in the life of p53. Nature 1993;362:786–787.
    External Resources
  15. Lane DP: Cancer, p53 guardian of the genome. Nature 1992;358:15–16.
    External Resources
  16. Finlay CA, Hinds PW, Tan HT, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms a hsc 70-p53 complex with altered half-time. Mol Cell Biol 1988;8:531–539.
    External Resources
  17. al Abadi H, Nagel R, Neuhaus P: Immunohistochemical detection of p53 protein in transitional cell carcinoma of the bladder in correlation to DNA ploidy and pathohistological stage and grade. Cancer Detect Prev 1998;22(1):43–50.
  18. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA: The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998;29(2):146–154.
  19. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480–487.
    External Resources
  20. Huober J, Sprenger H, Costa SD, Zentgraf H, Schmid H, Kaufmann M, Bastert G: Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma (in German). Zentralbl Gynkol 1996;118(10):560–564.
  21. Willsher PC, Pinder SE, Robertson L, Nicholson RI, Ellis IO, Bell JA, Blamey RW, Green JA, Robertson JF: The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 1996;16(2):927–930.
  22. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis EP: Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer 1996;78(10):2146–2152.
  23. Komiya T, Hirashima T, Takada M, Masuda N, Yasumitsu T, Nakagawa K, Hosono Y, Kikui M, Tsuji S, Fukoaka M, Kawase I: Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res 1997;17:37213724.
  24. Kaur J, Srivastava A, Ralhan R: Serum p53 antibodies in patients with oral lesions: Correlation with p53/HSP70 complexes. Int J Cancer 1997;74(6):609–613.
  25. Raedle J, Oremek G, Welker M, Roth WK, Caspary WF, Zeuzem S: p53-autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas 1996;13(3):241–246.
  26. Maass JD, Gottschlich S, Lippert BM, Niemann AM, Gorogh T, Werner JA: Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system (in German). Laryngorhinootologie 1996;75(1):53–56.
  27. Lang C, Unteregger G, Kartarius S, Gunther J, Bonkhoff H, Montenarh M, Zwergel T: p53 autoantibodies in patients with urological tumours. Br J Urol 1998;82(5):721–726.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: April 20, 2000
Issue release date: April 2000

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2000, Vol.64, No. 1

April 2000

Article

Recommend This
TOP